DiscoveryProbe FDA-approved Drug Library: Empowering High-Throughput Screening and Drug Repositioning

Principle and Setup: The Power of an FDA-Approved Bioactive Compound Library

The DiscoveryProbe™ FDA-approved Drug Library (SKU: L1021) from APExBIO is a meticulously curated collection of 2,320 bioactive compounds that have already secured approval from key regulatory bodies such as the FDA, EMA, HMA, CFDA, and PMDA, or are featured in major pharmacopeias. This comprehensive high-throughput screening drug library features a spectrum of mechanisms—ranging from receptor agonists and antagonists, enzyme inhibitors, and ion channel modulators, to signal pathway regulators. Pre-dissolved at 10 mM in DMSO and offered in user-friendly 96-well plates, deep-well formats, or barcoded tubes, the collection is optimized for high-content screening, pharmacological target identification, and robust drug repositioning.

By leveraging only FDA-approved or clinically characterized compounds, this library drastically reduces the translational gap, streamlining the path from bench discoveries to potential clinical applications. Its stability profile—12 months at -20°C and up to 24 months at -80°C—ensures consistent, reproducible results critical for longitudinal studies and multi-site collaborations.

Step-by-Step Workflow: Enhancing Screening Protocols with DiscoveryProbe

1. Plate Setup and Compound Handling

• Equilibrate plates containing the high-content screening compound collection to room temperature before opening to minimize condensation and avoid DMSO precipitation.
• For HTS campaigns, transfer desired compound volumes (typically 100–500 nL per well) using an automated liquid handler or acoustic dispenser to assay-ready plates. The 10 mM stock allows flexibility for serial dilution and dose-response studies.

2. Cell Seeding and Treatment

• Seed cells at optimal density, allowing for overnight adherence or recovery if necessary. For cancer research drug screening (e.g., AML, solid tumors), densities between 2,000-10,000 cells/well (96- or 384-well format) are common.
• Add compounds directly to cells in assay media, aiming for final DMSO concentrations ≤0.5% to minimize cytotoxic solvent effects.

3. Endpoint Readouts

• After 24–72 hours of incubation, assess viability (CellTiter-Glo, resazurin, or similar), apoptosis (Annexin V/PI or Caspase-Glo), or pathway modulation (luciferase reporter, western blotting, high-content imaging).
• For pharmacological target identification, combine with omics profiling (RNA-seq, proteomics) or CRISPR-based genetic screens.

4. Data Analysis and Hit Prioritization

• Normalize data to DMSO controls, calculate Z' factors (≥0.5 indicates robust assay performance), and prioritize hits based on pre-set activity thresholds (e.g., ≥50% inhibition or activation).
• Deconvolute hits by referencing compound annotations (mechanism, clinical stage) included in the DiscoveryProbe™ database.

Advanced Applications and Comparative Advantages

Case Study: Accelerating AML Drug Discovery and Mechanistic Elucidation

Recent research demonstrates the translational impact of systematic drug repositioning using FDA-approved bioactive compound libraries. In a landmark study (Wei Yang et al., 2025), investigators employed a small molecule drug library to identify mebendazole (MBD), a well-known antiparasitic, as a potent inducer of PANoptosis in acute myeloid leukemia (AML) cells. Through high-throughput viability assays, cell cycle analyses, and omics workflows, MBD was shown to target TUBA1A (tubulin alpha 1A), promote ZBP-1-mediated PANoptosis, and demonstrate in vivo efficacy in AML xenograft models. This study underscores the unique power of the DiscoveryProbe FDA-approved Drug Library for:

• Drug repositioning screening: Rapidly evaluating thousands of safe-in-human compounds for new indications such as cancer or neurodegenerative disease drug discovery.
• Pharmacological target identification: Linking compound-induced phenotypes to specific molecular targets and pathways (e.g., TUBA1A inhibition and ZBP-1 activation in AML).
• Signal pathway regulation: Mapping how clinically relevant modulators affect apoptosis, cell cycle, and inflammatory signaling.

The DiscoveryProbe™ platform’s annotation depth and compound diversity enable multiparametric screens targeting enzyme inhibitor activity, receptor modulation, and ion channel function, far surpassing generic libraries in translational value.

Integration with Cutting-Edge Research: Literature Interlinks

• DiscoveryProbe™ FDA-approved Drug Library: Next-Gen Screening for Antivirals: This article complements the present discussion by detailing how the same compound library is leveraged for high-throughput viral protease inhibitor identification, expanding its utility to infectious disease research.
• DiscoveryProbe™ FDA-approved Drug Library: Enabling Precision Immuno-Oncology: Extends on the current focus by delving into immuno-oncology and pathway modulation applications, illustrating the breadth of disease models accessible with this resource.
• Scenario-Driven Troubleshooting: Contrasts by offering practical, scenario-based troubleshooting insights for optimizing cell viability and screening workflows, directly addressing common experimental challenges highlighted below.

Troubleshooting and Optimization: Overcoming Common Challenges

1. DMSO-Related Cytotoxicity

Problem: High DMSO concentrations can induce off-target cytotoxicity, confounding hit identification.

Solution: Dilute compound stocks such that the final DMSO concentration in assay wells does not exceed 0.5% (v/v), and always include matched DMSO vehicle controls. Pre-equilibrate plates to avoid DMSO crystallization.

2. Plate Edge Effects and Evaporation

Problem: Peripheral wells may show aberrant results due to evaporation or temperature gradients during incubation.

Solution: Use plate seals and humidified chambers. Consider omitting outer wells or using buffer-filled border wells to minimize artefacts.

3. Compound Precipitation and Solubility

Problem: Some hydrophobic compounds may precipitate or adsorb to plastic surfaces, reducing effective concentrations.

Solution: Mix plates gently but thoroughly after thawing. For problematic compounds, perform a rapid visual inspection or employ absorbance-based solubility checks. Consider pre-coating wells with serum proteins or using low-binding plates for highly lipophilic compounds.

4. Assay Interference and Signal Quenching

Problem: Certain drugs (e.g., colored or autofluorescent compounds) may interfere with optical readouts, especially in high-content screening.

Solution: Cross-validate hits using orthogonal readouts (e.g., replace resazurin with ATP-based CellTiter-Glo). When possible, refer to compound annotation files provided by APExBIO for known interference profiles.

5. Reproducibility and Data Quality

Problem: Variability between runs or laboratories can hinder hit validation and downstream analysis.

Solution: The DiscoveryProbe™ FDA-approved Drug Library’s stability (≥12 months at -20°C) and precise barcoding enable robust tracking and reproducibility. Employ standardized data normalization (Z' factor, robust Z-scores) and include inter-plate controls for longitudinal studies.

Future Outlook: Expanding Horizons in Drug Discovery

As the biomedical landscape evolves, the demand for rapid, cost-effective, and translatable discovery tools intensifies. The DiscoveryProbe FDA-approved Drug Library, with its regulatory-vetted, mechanism-annotated compound portfolio, is positioned as an essential resource for next-generation screening platforms. Its proven utility in diverse settings—from AML PANoptosis research (Wei Yang et al., 2025) to antiviral and immuno-oncology studies—demonstrates how a single library can drive breakthroughs in both mechanistic biology and clinical translation.

Looking ahead, integrating this high-throughput screening compound collection with emerging technologies—such as single-cell analytics, CRISPR-based functional genomics, and AI-driven hit triage—will further accelerate the identification of novel targets and repositioned therapeutics. Data-driven insights from large-scale screens (e.g., Z' factors consistently >0.7, hit rates up to 2–5% in disease-relevant models) underscore the platform’s robustness and scalability.

In summary, APExBIO’s DiscoveryProbe™ FDA-approved Drug Library stands at the nexus of bench innovation and translational impact. By streamlining workflows, minimizing experimental pitfalls, and expanding the scope of drug repositioning screening, it empowers researchers to tackle complex challenges in cancer, neurodegeneration, and beyond with unprecedented efficiency and confidence.